

Kosei Hasegawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3307128/publications.pdf>

Version: 2024-02-01

38
papers

787
citations

623734

14
h-index

552781

26
g-index

38
all docs

38
docs citations

38
times ranked

1240
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma. <i>BMC Cancer</i> , 2022, 22, 59.	2.6	3
2	Identification of a Novel Oncogenic Fusion Gene SPON1-TRIM29 in Clinical Ovarian Cancer That Promotes Cell and Tumor Growth and Enhances Chemoresistance in A2780 Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 689.	4.1	2
3	Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826. <i>Cancer Science</i> , 2022, 113, 3877-3887.	3.9	11
4	Immunogenomic landscape of gynecologic carcinosarcoma. <i>Gynecologic Oncology</i> , 2021, 160, 547-556.	1.4	8
5	Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e16.	2.2	8
6	Transcriptomic analysis of hormone-sensitive patient-derived endometrial cancer spheroid culture defines Efp as a proliferation modulator. <i>Biochemical and Biophysical Research Communications</i> , 2021, 548, 204-210.	2.1	3
7	Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). <i>Journal of Clinical Oncology</i> , 2021, 39, 3671-3681.	1.6	84
8	Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e21.	2.2	7
9	Long Intergenic Noncoding RNA OIN1 Promotes Ovarian Cancer Growth by Modulating Apoptosis-Related Gene Expression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11242.	4.1	6
10	Adjuvant chemotherapy in patients with uterine carcinosarcoma: a review of clinical outcomes and considerations. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 247-255.	0.8	0
11	Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients. <i>Endocrine Journal</i> , 2020, 67, 219-229.	1.6	6
12	Current and future strategies for treatment of ovarian clear cell carcinoma. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 1678-1689.	1.3	9
13	High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e93.	2.2	8
14	Hormonal Regulation of Patient-Derived Endometrial Cancer Stem-like Cells Generated by Three-Dimensional Culture. <i>Endocrinology</i> , 2019, 160, 1895-1906.	2.8	15
15	Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. <i>Nature Communications</i> , 2019, 10, 4965.	12.8	82
16	Systematic Identification of Characteristic Genes of Ovarian Clear Cell Carcinoma Compared with High-Grade Serous Carcinoma Based on RNA-Sequencing. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4330.	4.1	21
17	Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma. <i>Gynecologic Oncology</i> , 2019, 155, 331-339.	1.4	9
18	Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years. <i>Surgical Oncology</i> , 2019, 29, 25-32.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. <i>Cells</i> , 2019, 8, 200.	4.1	6
20	Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma. <i>Modern Pathology</i> , 2019, 32, 1023-1031.	5.5	35
21	Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 2397.	3.3	21
22	Association of histone deacetylase expression with histology and prognosis of ovarian cancer. <i>Oncology Letters</i> , 2018, 15, 3524-3531.	1.8	29
23	Significance of venous thromboembolism in women with uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2018, 148, 267-274.	1.4	14
24	Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. <i>Journal of Surgical Oncology</i> , 2018, 117, 488-496.	1.7	15
25	Clinical utility of CA-125 in the management of uterine carcinosarcoma. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e88.	2.2	4
26	Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. <i>Gynecologic Oncology</i> , 2018, 151, 381-389.	1.4	99
27	Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element. <i>Surgical Oncology</i> , 2018, 27, 433-440.	1.6	12
28	Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 2756-2766.	1.5	5
29	Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 3676-3684.	1.5	14
30	Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 144, 329-335.	1.4	20
31	Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 145, 78-87.	1.4	31
32	Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 147, 565-571.	1.4	9
33	Phase II basket trial of perfosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations. <i>Investigational New Drugs</i> , 2017, 35, 800-812.	2.6	23
34	Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e25.	2.2	11
35	MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53. <i>Oncotarget</i> , 2016, 7, 75328-75338.	1.8	33
36	T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 6110-6117.	7.0	63

#	ARTICLE	IF	CITATIONS
37	Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. <i>Oncolmmunology</i> , 2015, 4, e1030561.	4.6	52
38	Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial. <i>Supportive Care in Cancer</i> , 2014, 22, 2891-2898.	2.2	8